InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2022-04-01 00:00:00 ET · period of report 2022-03-31 · accession 0001654954-22-004489 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-04-01 2022-03-31 MNPR Tsuchimoto Kim R CFO M - OptEx — +1,221 6,136 +25% —
D 2022-04-01 2022-03-31 MNPR Tsuchimoto Kim R CFO F - Tax $2.55 -500 5,636 -8% -$1,275
D 2022-04-01 2022-03-31 MNPR Tsuchimoto Kim R CFO M - OptEx $0.00 -1,221 77.4K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-03-31 M A 1,221 — 6,136 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
2 Common Common Stock 2022-03-31 F D 500 $2.55 5,636 D — —
3 Derivative Restricted Stock Units 2022-03-31 M D 1,221 $0.00 77,424 D — · — to — 1,221 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F2) On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.